Senti Biosciences (NASDAQ:SNTI) Announces Earnings Results

Senti Biosciences (NASDAQ:SNTI) posted its quarterly earnings data on Thursday. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.22, FiscalAI reports.

Senti Biosciences Price Performance

Shares of SNTI stock traded up $0.08 on Thursday, reaching $1.04. 532,506 shares of the stock were exchanged, compared to its average volume of 195,924. The stock has a market cap of $32.39 million, a PE ratio of -0.33 and a beta of 2.09. Senti Biosciences has a one year low of $0.77 and a one year high of $3.88. The stock has a 50 day moving average price of $0.95 and a 200 day moving average price of $1.23.

Institutional Investors Weigh In On Senti Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Jane Street Group LLC bought a new stake in shares of Senti Biosciences during the fourth quarter worth $40,000. Virtu Financial LLC bought a new stake in shares of Senti Biosciences during the fourth quarter worth $46,000. Citadel Advisors LLC bought a new stake in shares of Senti Biosciences during the third quarter worth $117,000. Geode Capital Management LLC raised its position in shares of Senti Biosciences by 395.6% during the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after acquiring an additional 117,588 shares during the last quarter. Finally, Armistice Capital LLC bought a new stake in Senti Biosciences in the second quarter valued at about $1,883,000. Institutional investors own 25.70% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on the company. Wall Street Zen raised Senti Biosciences from a “strong sell” rating to a “hold” rating in a research note on Saturday, March 28th. Weiss Ratings reissued a “sell (e+)” rating on shares of Senti Biosciences in a research note on Tuesday, April 21st. Finally, Chardan Capital reduced their price objective on Senti Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Monday, March 30th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $8.50.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.